Skip to Content
Merck
  • Maternal taurine supplementation attenuates maternal fructose-induced metabolic and inflammatory dysregulation and partially reverses adverse metabolic programming in offspring.

Maternal taurine supplementation attenuates maternal fructose-induced metabolic and inflammatory dysregulation and partially reverses adverse metabolic programming in offspring.

The Journal of nutritional biochemistry (2015-01-13)
M Li, C M Reynolds, D M Sloboda, C Gray, M H Vickers
ABSTRACT

Excessive fructose consumption is associated with insulin resistance (IR) and nonalcoholic fatty liver disease (NAFLD), and high fructose intake during pregnancy can lead to compromised fetal development in the rat. Evidence suggests that the amino acid taurine can ameliorate fructose-induced IR and NAFLD in nonpregnant animals. This study investigated the efficacy of taurine supplementation on maternal fructose-induced metabolic dysfunction and neonatal health. Time-mated Wistar rats were randomized to four groups during pregnancy and lactation: (a) control diet (CON), (b) CON supplemented with 1.5% taurine in drinking water (CT), (c) CON supplemented with fructose solution (F) and (d) F supplemented with taurine (FT). Maternal and neonatal weights, plasma cytokines and hepatic gene expression were analyzed. Maternal hyperinsulinemia, increased homeostasis model assessment of IR indices and elevated proinflammatory cytokines were observed in F group and normalized in FT group. Maternal fructose-induced hepatic steatosis accompanied with increased liver weight was ameliorated with taurine supplementation. Maternal hepatic sterol regulatory element-binding protein-1c and fatty acid synthase expression was significantly increased in the F group compared to the CON, CT and FT groups. Neonatal hepatic phosphoenolpyruvate carboxykinase expression was increased in male F neonates compared to the CON, CT and FT groups and was increased in female F and FT neonates compared to CON and CT. Interleukin-1β expression was decreased in male CT and FT neonates compared to other male groups. Hepatic tumour necrosis factor receptor-1 was lower in the male FT group than the F group. These results demonstrate that maternal taurine supplementation can partially reverse fructose-induced maternal metabolic dysfunction and may ameliorate adverse developmental programming effects in offspring in a sex-specific manner.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
D-(−)-Fructose, tested according to Ph. Eur.
Millipore
D-(−)-Fructose, ≥99.0% (HPLC), suitable for microbiology
Sigma-Aldrich
D-(−)-Fructose, BioUltra, ≥99.0% (HPLC)
Sigma-Aldrich
D-(−)-Fructose, ≥99% (HPLC), BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
D-(−)-Fructose, ≥99% (HPLC), BioXtra
Sigma-Aldrich
D-(−)-Fructose, 98.0-102.0% dry basis, meets USP testing specifications
Sigma-Aldrich
D-(−)-Fructose, ≥99% (HPLC)
Sigma-Aldrich
D-(−)-Fructose, SAJ special grade, ≥98.0%
USP
Fructose, United States Pharmacopeia (USP) Reference Standard
Supelco
Fructose, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
D-(−)-Fructose, analytical standard, analytical standard for fructose assay kit, for use with enzymatic assay kit FA20
Fructose, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Uric acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
Uric acid, ≥99%, crystalline
Sigma-Aldrich
DL-Homocysteine, ≥95% (titration)
Supelco
DL-Homocysteine, analytical standard